Late-Presenting Fulminant Immune Checkpoint Inhibitor Myocarditis Managed With Abatacept and Venoarterial Extracorporeal Oxygenation
Daniel S. Kikuchi, Edan Zitelny, Ashish Correa, Jonathan L. Halperin, Evan Leibner, Gregory W. Serrao, Gagan Sahni · 2026
Read Late-Presenting Fulminant Immune Checkpoint Inhibitor Myocarditis Managed With Abatacept and Venoarterial Extracorporeal Oxygenation by Daniel S. Kikuchi, Edan Zitelny, Ashish Correa, Jonathan L. Halperin, Evan Leibner, Gregory W. Serrao, Gagan Sahni (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13420715.txt.
Description
Daniel Kikuchi and co-authors report a rare, late case of heart inflammation caused by a cancer immunotherapy drug. Their 2026 case report describes a thirty-six-year-old man with colorectal cancer who arrived in cardiogenic shock after 460 days on pembrolizumab. Such drug-linked myocarditis usually strikes early in treatment, not over a year in.
Biopsy and clinical checks confirmed the diagnosis. High-dose steroids were not enough, and the man's heart and rhythm grew unstable. Doctors added a heart-lung support machine, the immune drug abatacept, and plasma exchange. His heart function recovered and the rhythm problems cleared. The authors urge vigilance for this side effect even late in therapy.
Catalog record
| CREATOR | Daniel S. Kikuchi, Edan Zitelny, Ashish Correa, Jonathan L. Halperin, Evan Leibner, Gregory W. Serrao, Gagan Sahni |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |